Finland's polypharmacy crisis: 145,000 elderly on 10+ medications

In Finland, 45.5% of adults aged 65 and older take five or more medications daily — well above the European average of 36.2%. Among those aged 75 and older, the situation is far more acute: 145,832 Finns in this age group are on ten or more medications simultaneously, representing 21% of the entire 75+ population. That number grows every year. What was once a clinical edge case — hyper-polypharmacy — has become the norm in Finnish elderly care, with consequences that ripple through patient safety, hospital admissions, and public healthcare spending.

This report examines the latest data on polypharmacy in Finland and the Nordics, its measurable impact on health outcomes and costs, and the evidence for what can be done about it.

The scale of Finland's polypharmacy problem

Finland's polypharmacy rates are among the highest in Europe. Data from the SHARE Wave 9 study (Survey of Health, Ageing and Retirement in Europe) shows that 45.5% of Finns aged 65+ use five or more medications concurrently, compared to the EU average of 36.2% (PMC11856818). Finland consistently ranks at or near the top of European polypharmacy tables.

The Finnish Medicines Agency Fimea tracks medication use through its national indicators. The most recent data reveals that 145,832 Finns aged 75 and older are taking ten or more medications — a threshold known as hyper-polypharmacy — and this figure has been increasing year over year. This is not a fringe population; it represents a full 21% of all Finns over 75.

The growth trajectory is driven by multiple factors: an aging population, the cumulative layering of prescriptions from multiple specialists, the reluctance to deprescribe medications in elderly patients, and the increasing prevalence of multimorbidity. Each new diagnosis tends to add medications without a corresponding review of the existing regimen.

Health consequences: a multiplied risk

Polypharmacy is not merely a matter of medication count — it is a direct multiplier of clinical risk. A 2024 study published in Frontiers in Pharmacology (fphar.2024.1382990) quantified the impact with striking clarity:

The risk extends beyond internal medicine. Falls are one of the most devastating consequences of polypharmacy in the elderly. Research shows that 33% of community-dwelling elderly people fall at least once per year (PMC4125318). Specific drug classes dramatically increase this risk:

In a population where a single hip fracture can trigger a cascade of immobility, institutional care, and decline, these are not abstract numbers. They represent thousands of preventable injuries and deaths every year in Finland alone.

The cost burden

Polypharmacy is not only a patient safety issue — it is an economic crisis. A systematic review published in BMC Geriatrics (PMC9313779) found that polypharmacy is associated with:

In Finland, the financial scale is substantial. According to Social Insurance Institution of Finland (Kela) data, the average annual prescription cost per person aged 75 and older reached EUR 1,127 in 2023. This figure has grown by 18.1% between 2020 and 2023 — an increase that outpaces general healthcare inflation and reflects both the growing number of prescriptions per patient and rising drug prices.

For a population of 145,832 Finns aged 75+ on ten or more medications, the direct pharmacy costs alone are enormous. But the indirect costs — emergency department visits, hospitalizations from adverse drug events, falls, extended care needs — multiply the economic burden many times over. When polypharmacy doubles total healthcare spending per patient, the aggregate national cost impact runs into hundreds of millions of euros annually.

Finnish home care: ground zero

If there is a single setting where the polypharmacy crisis is most acute, it is Finnish home care. The FIMA study (Finnish Investigation of Medication use Among home care patients), published in Clinical Interventions in Aging (PMC6763522), examined the medication burden of elderly home care patients and produced alarming findings:

These are not patients in hospital wards with continuous monitoring and pharmacy oversight. These are elderly people living at home, often alone, managing extraordinarily complex medication regimens with limited support. A patient taking 15 different medications may need to manage multiple dosing times, varying instructions (with food, without food, two hours apart from another drug), and changing prescriptions — all while potentially dealing with cognitive decline, vision impairment, or reduced manual dexterity.

The 74% rate of clinically relevant drug-drug interactions is particularly concerning. These are not theoretical risks flagged by conservative software algorithms — these are interactions identified as clinically significant by pharmacological review. In a home setting without real-time clinical oversight, these interactions go unmonitored until they produce symptoms, an emergency visit, or worse.

When errors become fatal

The consequences of polypharmacy-driven medication errors in Finland are not hypothetical. Data analyzed by Valvira (Finland's National Supervisory Authority for Welfare and Health) and published in Frontiers in Pharmacology (PMC8612921) examined reported medication safety incidents and found:

This is the population most affected by polypharmacy — and most vulnerable to its consequences. When a patient on 15 medications receives the wrong dose, misses a critical drug, or experiences an undetected interaction, the margin for error is essentially zero. The complexity of their regimen means that any single point of failure can cascade into a life-threatening event.

The 52% figure for death or severe harm deserves emphasis: this is not a rate of minor inconveniences or near-misses. More than half of reported medication incidents resulted in the most serious possible outcomes. Combined with the fact that medication incident reporting captures only a fraction of actual errors, the true toll is almost certainly higher.

Technology as a solution

The evidence base for technology-assisted medication management in Finland is growing. Two Finnish studies are particularly relevant:

The Finnish ADD study (Automated Dose Dispensing), published in BMC Geriatrics (PMC5730037), examined what happens when automated dose dispensing is combined with structured medication review. The study found that drug use decreased after the introduction of automated dispensing with medication review — in other words, the combination of technology and clinical oversight led to deprescribing and optimization, not just better adherence to an existing regimen. This is a critical finding: the technology itself becomes a catalyst for reducing inappropriate polypharmacy.

The Evondos study, published in BMC Health Services Research (PMC10693699), examined the impact of automated medication dispensing robots in Finnish home care and produced dramatic results:

These findings directly address the twin crises of polypharmacy management: patient safety and workforce capacity. When a dispensing robot ensures correct medications are available at the correct time, the need for a nurse to physically visit for medication administration drops dramatically. The freed-up time can be redirected to clinical assessment, medication review, and the kind of cognitive care work that actually improves outcomes.

The WHO's Third Global Patient Safety Challenge — "Medication Without Harm" — has set the goal of achieving a 50% reduction in severe preventable drug-related harm. Finland, with its high polypharmacy rates and advanced digital health infrastructure, is well-positioned to lead this effort — but only with the systematic adoption of technology that addresses the root causes of medication errors.

What MoniDose means for polypharmacy patients

The data in this report paints a clear picture of the challenge: too many medications, too many interactions, too many errors, and not enough hands to manage it all safely. MoniDose is designed to address each of these failure points in the medication chain:

The polypharmacy crisis in Finnish elderly care is not a problem that can be solved by awareness alone. It requires infrastructure — reliable, automated, data-driven systems that make safe medication management possible in the settings where patients actually live. That is what MoniDose is built to deliver.

Sources: